

Alzheimer's Vaccine


PROBLEM

Your patient suffers from the degenerative effects of Alzheimer's disease

SOLUTION

Alzheimer's vaccination, offered through a clinical trial

*Joshua Turknett, M.D.
Neurology*



Over four million Americans are stricken with Alzheimer's disease, a degenerative disease which involves abnormal protein folding in the brain. These abnormalities, called amyloid plaques, are thought to be the cause of impaired memory in Alzheimer patients. Current clinical trials specific to the study of Alzheimer's disease theorize that memory may be improved if amyloid plaques are removed or formation of plaques is prevented.

Since 1993, Dekalb Neurology Associates, LLC (DNA), has specialized in neurology research at DeKalb Medical and is now a leader in the field of clinical neurology research. DNA is one of only three sites in Georgia to offer Elan's new Alzheimer's Vaccine.

Dr. Joshua Turknett, along with his partners Drs. David Olson and Dr. Marshall Nash, have begun enrollment in two new Alzheimer Treatment trials. The two trials are underwritten by Elan and Wyeth Pharmaceutical Companies. Both trials are double blinded and placebo controlled.

Phase III: Alzheimer vaccine Bapinunzumab is a monoclonal antibody that is given every 13 weeks to qualified patients in double blind fashion. This drug binds to the Alzheimer amyloid plaque and allows the body's immune system to remove the plaque.

Phase II: Scylloinositol: This is an earlier phase trial designed to prevent formation of Alzheimer amyloid plaques.

Both trials are in the enrollment period that is expected to end in June of 2009.

For more information, call Dekalb Neurology Associates, LLC, at 404.508.4008.